Medtronic (MDT) Announces FDA Approval for Expanded Indication of OmniaSecure

Medtronic plc (NYSE:MDT) is one of the  7 Most Undervalued Blue Chip Stocks to Invest In.

On March 23, 2026, Medtronic plc (NYSE:MDT) received U.S. FDA approval for an expanded indication for its OmniaSecure defibrillation lead, now allowing placement in the left bundle branch area for conduction system pacing. The company said this approach more closely mimics the heart’s natural physiology, with additional benefits for patients requiring cardiac resynchronization through combined pacing techniques.

On March 10, 2026, Medtronic plc (NYSE:MDT) announced a definitive agreement to acquire Scientia Vascular for $550M, with potential additional earn-out payments. The company said the deal, expected to close in the first half of FY27, will be minimally dilutive to adjusted EPS in FY27 and accretive thereafter. Scientia operates in Salt Lake City with approximately 310 employees.

Medtronic (MDT) Announces FDA Approval for Expanded Indication of OmniaSecure

al7/Shutterstock.com

Last month, Medtronic plc (NYSE:MDT) reported Q3 EPS of $1.36, above the $1.34 consensus estimate, on revenue of $9.02B versus $8.89B expected. CEO Geoff Martha said the company delivered “strong” performance with 6% organic revenue growth, highlighting continued investment in innovation and expansion into new markets to support long-term growth.

Medtronic plc (NYSE:MDT) develops and manufactures medical devices and therapies used across a range of healthcare applications.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.